Multiple sclerosis is not considered a rare disease. With close to 1 million people diagnosed in the United States alone and 2.9 million worldwide, MS far exceeds the thresholds that define rare conditions. That said, the relationship between MS and rare disease classifications is more complicated than a simple yes or no, because some MS therapies have received rare disease drug designations, and certain subtypes of MS are genuinely uncommon.
How Rare Diseases Are Defined
In the United States, the Orphan Drug Act defines a rare disease as one that affects fewer than 200,000 people. The European Medicines Agency uses a slightly different measure: a condition qualifies if it affects no more than 5 in 10,000 people across the European Union. Both thresholds exist primarily to encourage pharmaceutical companies to develop treatments for conditions that wouldn’t otherwise attract investment, since the potential patient population is so small.
MS Prevalence in the US and Globally
A 2019 prevalence study funded by the National MS Society found that almost 1 million people in the United States have received an MS diagnosis. That’s roughly 288 per 100,000 people, placing the US among the highest-prevalence countries in the world, behind only San Marino and Germany. For context, in the US, about 4 out of every 1,000 white non-Hispanic people have MS, about 3 out of every 1,000 Black non-Hispanic people, and about 1.5 out of every 1,000 Hispanic or Latino people.
Globally, 2.9 million people live with MS, a number that has climbed from 2.3 million in 2013. Prevalence varies dramatically by region. Countries in northern Europe and North America often exceed 200 per 100,000, while many countries in sub-Saharan Africa and Southeast Asia fall below 25 per 100,000. So while MS is clearly not rare in high-income northern-latitude countries, it can be genuinely uncommon in other parts of the world, which creates real problems with diagnostic delays and access to treatment in those regions.
Why MS Drugs Got Rare Disease Status
Here’s where things get confusing. Several major MS medications, including some of the earliest and most widely prescribed therapies, originally received orphan drug designations from the FDA. These designations were granted in the late 1980s and early 1990s, when MS prevalence estimates were significantly lower than they are today, and when specific subtypes of the disease were targeted rather than MS as a whole. Between MS and brain tumors, there have been 42 orphan drug designations and 9 approvals, making them among the most common neurological conditions to benefit from the orphan drug program.
Orphan drug designation comes with substantial financial incentives: tax credits, federal grants, and extended market exclusivity that protects companies from generic competition. The FDA’s orphan product grants program awards roughly $14 million per year across 10 to 15 new grants. These incentives were designed to make it profitable to develop drugs for tiny patient populations, but they’ve also been used strategically for conditions like MS that aren’t truly rare. Critics have pointed out that this can drive up drug costs. One example: a sustained-release version of a walking-improvement drug for MS costs approximately $12,850 per year with orphan status, while the generic short-acting version of the same compound costs less than $1,000 per year.
Subtypes That Are Genuinely Rare
While MS overall is a common neurological condition, some forms of the disease do qualify as rare. Pediatric-onset MS, diagnosed in children under 18, accounts for only 3 to 5 percent of all MS cases worldwide. The estimated yearly incidence in US children is between 0.18 and 0.65 per 100,000, which places it well within rare disease territory. Because MS is so strongly associated with adults, children with early symptoms often face significant diagnostic delays.
Even rarer is the Marburg variant, an aggressive form that represents fewer than 4 percent of MS cases and can progress rapidly to severe disability or death. Baló concentric sclerosis, another atypical variant, is similarly uncommon. These subtypes are rare enough that distinguishing them from brain infections, tumors, or other conditions that damage the protective coating of nerve fibers is a significant clinical challenge.
What This Means in Practical Terms
If you or someone you know has MS, the condition’s classification matters less for day-to-day life than for understanding the broader landscape of treatment and research funding. MS benefits from a large and active research community, numerous approved therapies, and well-established patient support networks, none of which would exist if the disease were truly rare. The National MS Society, advocacy organizations, and major academic medical centers all maintain dedicated MS programs precisely because the patient population is large enough to sustain them.
Where the rare disease question becomes personally relevant is if you or your child has one of the uncommon subtypes. Pediatric MS, Marburg MS, and other atypical variants have far fewer treatment studies, less clinical experience to draw on, and a higher risk of misdiagnosis. For those specific populations, the challenges look much more like those faced by people with genuinely rare conditions: fewer specialists, limited evidence-based treatment options, and a longer road to an accurate diagnosis.